Take Home MessageThere is substantial preference heterogeneity between patients regarding the expected survival benefits and potential adverse effects of systemic treatment for metastatic hormone-sensitive prostate cancer. Patients’ preferences regarding survival and treatment-related adverse effects should be explicitly discussed in clinical practice.